Live Feeds
● LIVE Updated 22h ago · 30 sources tracked

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

Federal regulators have awarded breakthrough therapy designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. This development builds on the prior approval of the medication under the brand name Rasonque, which previously established a milestone by doubling median survival rates compared to standard chemotherapy while targeting difficult RAS mutations. Five competing drugmakers are currently pursuing similar personalized cancer vaccine therapies following recent melanoma trials by Merck and Moderna. The expanded designation highlights ongoing acceleration in targeted oncology pipelines aimed at addressing refractory tumors.

RSS Source map (30)

What changed

The FDA granted breakthrough therapy designation to daraxonrasib when paired with chemotherapy for first-line treatment of metastatic pancreatic cancer.

Live updates

  1. FDA Grants Breakthrough Designation to Daraxonrasib

    Federal regulators have awarded breakthrough therapy designation to daraxonrasib combined with chemotherapy for first-line metastatic pancreatic cancer. This development builds on the prior approval of the medication under the brand name Rasonque, which previously established a milestone by doubling median survival rates compared to standard chemotherapy while targeting difficult RAS mutations. Five competing drugmakers are currently pursuing similar personalized cancer vaccine therapies following recent melanoma trials by Merck and Moderna. The expanded designation highlights ongoing acceleration in targeted oncology pipelines aimed at addressing refractory tumors.

    Why it matters

    Pancreatic cancer remains one of the most challenging diagnoses in oncology due to historically low survival rates and a lack of effective treatments against aggressive genetic drivers. The previous approval of daraxonrasib offered a rare clinical advance for metastatic disease and sparked broader industry competition in tailored oncology drugs. Regulatory recognition via breakthrough status aims to expedite development pathways for therapies addressing severe unmet medical needs.

    What is confirmed

    • The FDA granted breakthrough therapy designation to daraxonrasib plus chemotherapy in first-line metastatic pancreatic cancer.
    • Merck and Moderna lead the field in personalized cancer vaccines following a melanoma win last month.

    Still unconfirmed

    • Five different drugmakers are currently chasing Merck and Moderna in the cancer vaccine development race.

    What to watch next

    • Further clinical trial results from the five drugmakers pursuing personalized cancer vaccines
    • Regulatory updates on combination therapies involving daraxonrasib and chemotherapy
    Sources used for this update (5)
    1. jen.jiji.com — Italian Naval League, over 13,000 young people and the alliance with the Crusca to bring new generations closer to the sea
    2. jen.jiji.com — MotoGp, today San Marino Grand Prix - Live
    3. www.biospace.com — 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
    4. jen.jiji.com — Serie A, today Inter-Udinese 0-0 - Live
    5. oncodaily.com — FDA Grants Breakthrough Therapy Designation to Daraxonrasib Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer
    confidence 90%

  2. FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

    The FDA has approved daraxonrasib, marketed as Rasonque, for the treatment of metastatic pancreatic cancer. The drug targets RAS and doubles median survival rates compared to chemotherapy. While primarily approved for pancreatic cancer, early trials indicate the medication may also be effective against treatment-resistant lung cancer. This approval addresses one of the most difficult targets in oncology and provides a long-awaited treatment advance for patients with metastatic disease.

    Why it matters

    Pancreatic cancer has historically lacked effective targeted therapies. The introduction of RAS-targeting drugs like Rasonque represents a shift toward precision medicine in oncology. This development follows broader industry struggles with drug delivery and insurance access.

    What is confirmed

    • The FDA approved daraxonrasib for the treatment of metastatic pancreatic cancer.
    • Daraxonrasib targets RAS in metastatic pancreatic cancer and doubles median survival versus chemotherapy.
    • Daraxonrasib is marketed under the name Rasonque.

    Still unconfirmed

    • Daraxonrasib may help fight treatment-resistant lung cancer.

    What to watch next

    • Results from early trials regarding lung cancer efficacy
    • Insurance coverage determinations for Rasonque
    • Long-term survival data beyond the median survival increase
    Sources used for this update (5)
    1. www.theglobeandmail.com — Globe Investor
    2. jen.jiji.com — Fuel prices, Council of Ministers approves 7-day extension of excise duty cut
    3. www.yahoo.com — A New Drug Takes Aim At One Of Cancer’s Most Difficult Targets
    4. www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
    5. jen.jiji.com — Goodbye heat, mugginess finally out of play: this weekend all of Italy in green, how long will it last
    confidence 100%

  3. Moonwalk Biosciences Secures $70M for Obesity RNAi Therapies

    Moonwalk Biosciences has successfully raised $70 million in a Series B funding round to advance adipose-targeted RNAi obesity therapies, drawing new investment from Eli Lilly. This funding injection arrives as patients increasingly seek alternative treatments outside standard regulated health systems, fueling a broader boom in peptide and injectable care. Meanwhile, the biotechnology industry continues to face complex hurdles in drug delivery and insurance access following recent regulatory approvals for critical oncology treatments like Revolution Medicines' Rasonque.

    Why it matters

    The financing highlights intense commercial interest in novel therapeutic formats like RNAi and peptides as demand surges for advanced metabolic and obesity treatments. Companies are racing to develop next-generation interventions that bridge the gap between regulatory clearance and patient accessibility. Private capital continues to flow heavily into biotech firms developing targeted genetic and metabolic therapies.

    What is confirmed

    • Moonwalk Biosciences raised a $70M Series B for adipose-targeted RNAi obesity therapies.
    • Eli Lilly joined Moonwalk Biosciences as a new investor.

    Still unconfirmed

    • Patients are looking beyond the regulated health system to address problems that doctors have struggled to treat.

    What to watch next

    • Clinical trial timelines for Moonwalk Biosciences adipose-targeted RNAi therapies
    • Further investment or partnership announcements involving Eli Lilly and obesity drug developers
    Sources used for this update (4)
    1. jen.jiji.com — Now, British-Israeli rabbi writes to UK PM criticizing hypocrisy in treatment of Israelis
    2. jen.jiji.com — "Artificial Intelligence can kill us all in 10 years", the researcher's warning
    3. www.smithsonianmag.com — Peptides Are All the Rage, Promising Miracle Cures and Makeovers Delivered by Injection. How Did We Get Here?
    4. en.wowtale.net — Moonwalk Biosciences Raises $70M for Adipose-Targeted RNAi
    confidence 100%

  4. FDA Approves Rasonque for Pancreatic Cancer Amid Insurance Delays

    The FDA approved Rasonque, a pancreatic cancer drug from Revolution Medicines, last month. While the drug marks the end of a long development quest, patients are currently struggling to access the treatment because insurance coverage often takes weeks to catch up with regulatory approval. Rasonque previously showed the ability to double median survival rates for pancreatic cancer patients who failed prior systemic therapies and is currently being investigated for efficacy in advanced lung cancer.

    Why it matters

    Revolution Medicines designed Rasonque for metastatic pancreatic adenocarcinoma. Researchers are now testing if the drug can treat other aggressive cancers or younger patient populations. This follows a broader medical effort to expand targeted cancer therapies.

    What is confirmed

    • The FDA approved Rasonque for the treatment of pancreatic cancer last month.
    • Patients face delays in accessing Rasonque because insurance coverage can take weeks to follow FDA approval.
    • Rasonque is developed by Revolution Medicines.

    What to watch next

    • Insurance providers' timelines for updating coverage for Rasonque
    • Clinical trial results for Rasonque in advanced lung cancer patients
    Sources used for this update (7)
    1. www.dailymail.com — How to ditch your blood pressure pills: Fed up with side effects or worried about the dangers? These are the simple changes that could help you get off the medication f…
    2. www.dailymail.com — As Thomasina Miers reveals she followed an intermittent low calorie diet during chemotherapy, why research suggests FASTING may boost some cancer treatments
    3. www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
    4. jen.jiji.com — Malagò's failed FIGC registration, Coni prosecutor rejects request for dismissal
    5. www.omanobserver.om — Race begins to more medicines like new pancreatic cancer drug
    6. jen.jiji.com — Oasis in Rome in 2027, two concerts in July on the Sun's calendar
    7. medicalxpress.com — Dual-drug approach burns out leukemia cells by pressing accelerator and brake simultaneously
    confidence 100%

  5. Rasonque Trials Expand Following Success in Pancreatic Cancer

    Rasonque, a daily pill developed by Revolution Medicines, is under investigation for advanced lung cancer after doubling median survival rates for pancreatic cancer patients who failed prior systemic therapies. Early clinical trials indicate one-third of lung cancer patients experienced tumor shrinkage. While originally designed for metastatic pancreatic adenocarcinoma, larger trials are now determining if the drug's efficacy extends to other cancer types. This effort is part of a broader medical push to identify and treat aggressive cancers, including those appearing in younger populations.

    Why it matters

    The FDA-approved drug targets specific mutations to treat advanced malignancies. Its success in pancreatic cancer established a baseline for efficacy in difficult-to-treat tumors. Researchers are now testing its versatility across different organ systems.

    What is confirmed

    • Rasonque is a daily pill developed by Revolution Medicines for metastatic pancreatic adenocarcinoma.
    • The drug doubled median survival rates for pancreatic cancer patients who failed prior systemic therapies.
    • One-third of patients with advanced lung cancer experienced tumor shrinkage in an early clinical trial.

    What to watch next

    • Results from larger trials regarding the drug's efficacy in lung cancer
    • FDA updates on expanded indications for Rasonque
    Sources used for this update (5)
    1. www.dailymail.com — The group of 'superfoods' that naturally lowers dangerously high blood pressure
    2. jen.jiji.com — Francesca Pascale celebrates Meloni government in Bari: "Berlusconi would be proud"
    3. jen.jiji.com — Back to school: ISS mini-guide for parents and children against anxiety
    4. www.usatoday.com — AI is helping get new medicines to patients sooner. Here's how
    5. www.dailymail.com — Sam thought her 'funny tummy' was caused by gluten or even IBS. Then she discovered the true culprit... a little-known cancer that's on the rise - and it's NOT c…
    confidence 100%

  6. Pancreatic Cancer Drug Rasonque Shows Potential for Lung Cancer Treatment

    The FDA-approved drug Rasonque, also known as daraxonrasib, is showing early potential to treat advanced lung cancer. In an early clinical trial, one-third of patients with advanced lung cancer experienced tumor shrinkage. The medication, originally developed by Revolution Medicines for metastatic pancreatic adenocarcinoma, is a daily pill that researchers call a landmark development. Larger trials are currently underway to determine if the drug's efficacy extends beyond pancreatic cancer. This follows the drug's success in doubling median survival rates for pancreatic cancer patients who failed prior systemic therapies.

    Why it matters

    Rasonque targets a gene previously viewed as undruggable, based on foundational work from University of Cincinnati researchers. The drug is an oral multi-selective RAS(ON) inhibitor. Its ability to potentially treat multiple cancer types suggests a broader application for RAS-inhibiting therapies.

    What is confirmed

    • The FDA approved Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or failed one prior systemic therapy.
    • Rasonque is a daily pill and an oral multi-selective RAS(ON) inhibitor.
    • The drug doubled median survival rates in the RASolute 302 trial.
    • Revolution Medicines developed the drug using foundational work from University of Cincinnati researchers.

    Still unconfirmed

    • One-third of patients with advanced lung cancer saw tumors shrink in an early clinical trial.
    • Combining RAS(ON) inhibitors with other therapies could help patients overcome immunotherapy resistance.
    • One individual remained cancer-free for more than two years using combined therapies.

    What to watch next

    • Results from the larger lung cancer clinical trials currently underway.
    • Further data on the efficacy of combining Rasonque with immunotherapies.
    Sources used for this update (6)
    1. jen.jiji.com — US Open, Guerrieri's dream ends: De Minaur dismisses the Italian in three sets and advances to the second round
    2. www.medicalbrief.co.za — FDA approval of landmark pancreatic cancer drug hailed by experts
    3. www.nbcnews.com — Newly approved pancreatic cancer drug shows promise in lung cancer
    4. jen.jiji.com — Tragedy in Finale Ligure: father, mother, and 15-year-old son found dead at home. Hypothesis of murder-suicide
    5. jen.jiji.com — De Martino returns with Affari Tuoi, the novelties: from the 'versatile' studio to Tommasino
    6. abcnews.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
    confidence 90%

  7. UC Researchers Helped Develop FDA-Approved Pancreatic Cancer Drug

    The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic adenocarcinoma who failed or are ineligible for one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. University of Cincinnati researchers contributed the foundational work for the treatment, which targeted a gene previously considered undruggable. Early-stage data published in Nature Communications suggests combining such therapies could help patients overcome immunotherapy resistance, with one individual remaining cancer-free for more than two years.

    Why it matters

    Pancreatic cancer has long lacked effective targeted therapies due to the difficulty of inhibiting specific genetic mutations. Rasonque's approval follows a national priority voucher filing that accelerated the process by five weeks. This development marks a shift in treating metastatic adenocarcinoma by successfully targeting the RAS gene.

    What is confirmed

    • The FDA approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have failed one prior systemic therapy.
    • Rasonque doubled median survival rates in the RASolute 302 trial.
    • Revolution Medicines developed Rasonque.
    • University of Cincinnati researchers helped lay the groundwork for the treatment.

    What to watch next

    • Clinical trial results for combination therapies to overcome immunotherapy resistance
    • Further data on long-term survival rates beyond the RASolute 302 trial
    Sources used for this update (5)
    1. www.wcpo.com — 'This is the beginning’ | UC researchers helped tackle an ‘undruggable’ target in pancreatic cancer
    2. finance.yahoo.com — MassLive’s Most Influential Innovators of 2026
    3. jen.jiji.com — Primark, 500th store opened in Pompeii: 8 million euros invested and 150 new jobs created
    4. www.sandiegouniontribune.com — Paul Sisson
    5. www.yahoo.com — Editorial Roundup: United States
    confidence 100%

  8. FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

    The FDA approved Rasonque (daraxonrasib), an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who are ineligible for or have failed one prior systemic therapy. Developed by Revolution Medicines, the drug doubled median survival rates in the RASolute 302 trial. The approval occurred five weeks after the company filed using a national priority voucher. While Rasonque targets a previously undruggable gene, separate early-stage trial results published in Nature Communications suggest combination therapies may help patients overcome immunotherapy resistance, with one patient remaining cancer-free for over two years.

    Why it matters

    Pancreatic cancer has long been considered intractable due to limited treatment options and resistance to immunotherapy. The approval of the first broad RAS-targeted therapy represents a shift in how physicians treat metastatic cases. This development follows decades of limited progress in improving survival times for the disease.

    What is confirmed

    • The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or cannot undergo multiagent systemic therapy.
    • Rasonque is an oral pill that doubled median survival rates compared to chemotherapy.
    • Revolution Medicines developed Rasonque as the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer.
    • The FDA granted approval roughly five weeks after the filing under a national priority voucher.

    Still unconfirmed

    • One patient in an early-stage combination therapy trial experienced a pathologic complete response and has remained cancer-free for more than two years without further treatment.
    • Revolution Medicines reached a market valuation of $47 billion with shares hitting an all-time high above $224 on August 27, 2026.

    What to watch next

    • Clinical trial results for combination therapies targeting immunotherapy resistance.
    • Long-term survival data from patients receiving Rasonque at institutions like Dartmouth.
    Sources used for this update (4)
    1. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
    2. medicalxpress.com — New combination therapy shows promise in metastatic pancreatic cancer
    3. finance.yahoo.com — Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
    4. www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
    confidence 95%

  9. FDA Approves RASONQUE for Pancreatic Cancer Treatment

    The FDA approved RASONQUE (daraxonrasib) on August 26, 2026, as a once-daily oral pill for pancreatic cancer. The drug doubled median survival rates compared to chemotherapy. Experts suggest the treatment could transform care for a disease long considered intractable, as it targets a gene previously viewed as undruggable. Patients at institutions including Dartmouth are among the first to receive the medication.

    Why it matters

    Pancreatic cancer is one of the deadliest forms of the disease and has remained difficult to treat for decades. This approval follows long-term research efforts to find a breakthrough for the condition.

    What is confirmed

    • The FDA approved RASONQUE (daraxonrasib) on August 26, 2026.
    • RASONQUE is a once-daily oral pill.
    • The drug doubled median survival rates compared to chemotherapy.
    • The FDA announced the approval on Wednesday.

    What to watch next

    • Clinical data on long-term survival rates beyond the initial median doubling
    • Expansion of the drug's approved use to other cancer types
    • Development of additional medicines targeting the same gene pathway
    Sources used for this update (12)
    1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
    2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
    3. Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
    4. Scientific American — U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
    5. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
    6. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
    7. Cleveland.com — For decades, researchers chased a breakthrough. Now it has finally arrived
    8. WMUR — Dartmouth patients among first to get new drug that fights pancreatic cancer
    9. www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
    10. www.gainesville.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
    11. medicalxpress.com — FDA approves new treatment for hard-to-treat pancreatic cancer
    12. www.yahoo.com — The Drug That Finally Cracked Pancreatic Cancer’s “Undruggable” Gene
    confidence 100%